The respiratory research group is based in the Daisy Clinical Research and Teaching Building (2nd floor), Castle Hill Hospital
We use a translational biology "bench to bedside" approach to address research questions in pulmonary fibrosis and sarcoidosis.
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lungs that affects 15,000 people in the UK. We believe that development of effective therapies in the future will depend on a better understanding of what initiates and perpetuates lung scarring.
- We have discovered abnormalities of platelet function in patients with IPF. We are studying how the pulmonary vascular endothelium responds to injury and how these responses contribute to pulmonary fibrosis by promoting retention and activation of platelets in the lungs.
- Pulmonary fibrosis commonly complicates rheumatic diseases, and a related research theme is exploring the relationship between autoimmunity and lung inflammation and fibrosis.
- We are developing novel imaging techniques in pulmonary fibrosis, both in the lab (in collaboration with Hull University Dept. of chemistry) and in the clinic.
- We have an ongoing interest in assessing and treating symptoms in pulmonary fibrosis, particularly breathlessness and cough.
Sarcoidosis is a chronic inflammatory disease of unknown cause, characterised by hyper-activation of immune cells. Whilst some cases remit spontaneously, there is no curative treatment.
- We are studying immune responses in the blood and lung tissue of patients with sarcoidosis to help understand how the disease is initiated and driven. We are particularly interested in how abnormal function of regulatory (inhibitory) receptors on blood monocytes leads to an overactive immune system in sarcoidosis.
Thanks to our current funders - British Lung Foundation, Sir Jules Thorn Charitable Trust, Boehringer Ingelheim
Reigada C, Papadopoulos A, Boland JW, Yorke J, Ross J, Currow DC, Hart S, Bajwah S, Grande G, Wells A, Johnson MJ. Implementation of the Needs Assessment Tool for patients with interstitial lung disease (NAT:ILD): facilitators and barriers. Thorax 2017 Feb 20. doi:10.1136
Hart, SP. (2017). Idiopathic Pulmonary Fibrosis. [podcast] The Lancet Respiratory Medicine: January 2017. Available at: http://www.thelancet.com/lanres/audio [Accessed 3 Jan 2017]
Fraser SD, Sadofsky LR, Kaye PM, Hart SP. Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis. Sci Rep. 2016 Dec 8;6:38689.
Williamson JD, Sadofsky LR, Crooks MG, Greenman J, Hart SP. Bleomycin increases neutrophil adhesion to human vascular endothelial cells independently of upregulation of ICAM-1 and E-selectin. Exp Lung Res. 2016;42(8-10):397-407. doi: 10.1080/01902148.2016.1243742. PubMed PMID: 27797602
Trawinska MA, Rupesinghe RD, Hart SP. Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2016 Apr 8;12:563-74
Boland JW, Reigada C, Yorke J, Hart SP, Bajwah S, Ross J, Wells A, Papadopoulos A, Currow DC, Grande G, Macleod U, Johnson MJ. The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease. J Palliat Med. 2016 May;19(5):549-55
Crooks MG, Hart SP. Coagulation and anticoagulation in idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Sep;24(137):392-9
Johnson MJ, Simpson MIG, Currow DC, Millman RE, Hart SP, Green G. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. BMJ Open 2015;5:6 e007535
Crooks MG, Hart SP. Biomarkers in idiopathic pulmonary fibrosis: picking the winners for trials. The Lancet Respiratory Medicine 2015;3:421-2
Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Experimental lung research 2015; 41(2): 57-73.
Crooks MG, Hart SP. A new era of drug therapy for idiopathic pulmonary fibrosis. The Lancet Respiratory Medicine 2014; 2(12): 964-6.
Crooks MG, Fahim A, Naseem KM, Morice AH, Hart SP. Increased platelet reactivity in idiopathic pulmonary fibrosis is mediated by a plasma factor. PloS one 2014; 9(10): e111347.
Hart SP. Understanding CT patterns in idiopathic pulmonary fibrosis. Lancet Respir Med. 2014 Apr;2(4):249-50.
Fahim A, Crooks MG, Morice AH, Hart SP. Increased platelet binding to circulating monocytes in idiopathic pulmonary fibrosis. Lung. 2014 Apr;192(2):277-84.
Fahim A, Crooks MG, Wilmot R, Campbell AP, Morice AH, Hart SP. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respirology. 2012;17:1247-52
Fahim A, Chong MC, Crooks MG, Hart SP. Idiopathic Pulmonary Fibrosis is Associated with Circulating Antiepithelial Antibodies. Lung. 2012;190:451-458
Hart SP, Rossi AG, Haslett C, Dransfield I. Characterization of the Effects of Cross-Linking of Macrophage CD44 Associated with Increased Phagocytosis of Apoptotic PMN. PLoS One. 2012;7(3):e33142
Fahim A, Crooks M, Hart SP. Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med. 2011;2011:634613
Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis. Respiration.2011;81:142-9.
Goh YC, Yap CT, Huang BH, Cronshaw AD, Leung BP, Lai PB, Hart SP, Dransfield I, Ross JA. Heat-shock protein 60 translocates to the surface of apoptotic cells and differentiated megakaryocytes and stimulates phagocytosis. Cell Mol Life Sci. 2011 68:1581-92.
Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. Lung. 2010;188:475-81
Bournazos S, Grinfeld J, Alexander KM, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. BMC Pulm Med. 2010;10:51.
Bournazos S, Fahim A, Hart SP. Identification of fibrocytes in peripheral blood. Am J Respir Crit Care Med. 2009;180:1279
Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol. 2009;157:244-54
Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol. 2009;182:8026-36
Kilpatrick DC, Chalmers JD, MacDonald SL, Murray M, Mohammed A, Hart SP, Matsushita M, Hill A. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J. 2009 Jan;3:29-33.
Bournazos S, Rennie J, Hart SP, Fox KA, Dransfield I. Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. Arterioscler Thromb Vasc Biol. 2008;28:1491-8.
Bournazos S, Rennie J, Hart SP, Dransfield I. Choice of anticoagulant critically affects measurement of circulating platelet-leukocyte complexes. Arterioscler Thromb Vasc Biol. 2008;28(1):e2-3
Hart SP, Dransfield I, Rossi AG. Phagocytosis of apoptotic cells. Methods 2008;44:280-285
Taylor EL, Rossi AG, Dransfield I, Hart SP. Analysis of neutrophil apoptosis. Methods Mol Biol. 2007;412:177-200
International Advisory Board, The Lancet Respiratory Medicine
Member of Council, British Thoracic Society
Member, BTS clinical guideline development group, Long Term Macrolide Therapy for Chronic Lung Disease
Member, BTS Standards of Care committee
Member, Examination Board of the Respiratory Specialist Certificate Examination, Royal College of Physicians
Trustee, Action for Pulmonary Fibrosis (http://www.actionpulmonaryfibrosis.org/)
Co-lead, Academic Foundation Program, Hull York Medical School
Member, Question Writing Group of the Respiratory Specialist Certificate Examination, Royal College of Physicians